Prevention and treatment of ocular inflammation with a new class of non-steroidal anti-inflammatory agents.
New non-steroidal anti-inflammatory agents (NSAIAs) were tested on lens protein-, endotoxin- and interleukin-1-induced ocular inflammation. It was found that most NSAIAs, including REV 5901, mefenamic acid, indomethacin, CK-17 and CK-102, inhibited lens protein-induced inflammation. Endotoxin induced inflammation indirectly through the release of IL-1 which was inhibited by fewer agents, including CK-17, CK-102 and prednisolone. However, the direct effect of IL-1 can only be suppressed by CK-17 and prednisolone. Therefore, CK-17 could become an important NSAIA which acts similarly to corticosteroids yet produces no steroidal side effects. CK-17 was different from most NSAIAs as it affected little, if any, arachidonate metabolism. Most importantly, CK-17 was found to be 2-fold more potent than prednisolone in inhibiting IL-1-induced uveitis, while no side effects were noted at doses tested to date.
Chiou
G C
GC
Institute of Ocular Pharmacology, Texas A&M University Health Science Center, College Station.
Yao
Q S
QS
Chang
M S
MS
Okawara
T
T
D000818:Animals; D000869:Anterior Eye Segment / Q000378:metabolism; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002634:Chemotaxis, Leukocyte; D003459:Crystallins; D005260:Female; D007962:Leukocytes; D015289:Leukotrienes / Q000096:biosynthesis; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D011453:Prostaglandins / Q000096:biosynthesis; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012160:Retina / Q000378:metabolism; D014605:Uveitis / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003459:Crystallins; D015289:Leukotrienes; D011453:Prostaglandins; D011239:Prednisolone